Drugs / ipriflavone
ipriflavone
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07236190 | Apr 2026 → Jun 2027 expected | Alzheimer disease, subjective cognitive decline | Massachusetts General Hospital | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ipriflavone | “parthenolide plus ipriflavone” NCT07236190 ↗ |
| Known as | 7-isopropoxyisoflavone | ChEMBL registry synonym — accepted as the source's own label CHEMBL165790 ↗ |
| Known as | Ipriflavona | ChEMBL registry synonym — accepted as the source's own label CHEMBL165790 ↗ |
| Known as | NSC-755888 | ChEMBL registry synonym — accepted as the source's own label CHEMBL165790 ↗ |
| Known as | Osten | ChEMBL registry synonym — accepted as the source's own label CHEMBL165790 ↗ |
| Known as | Ostivone | ChEMBL registry synonym — accepted as the source's own label CHEMBL165790 ↗ |
| Modality | Small molecule | — CHEMBL165790 ↗ |